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Background: DLBS3233 is a standardized extract combination containing Lagerstroemia 
speciosa and Cinnamomum burmannii. The effect of DLBS3233 on glucose uptake, adiponectin 
secretion, and insulin signaling was examined in this study.
Methods: 3T3 Swiss albino preadipocytes and adipocytes were used to investigate gene   expression 
detected using the reverse transcription polymerase chain reaction method. Immunoblotting assay 
and in vitro glucose uptake assay were also carried out in the experiment.
Results: DLBS3233 was seen to increase phosphorylation at the tyrosine residue of the insulin 
receptor substrate. DLBS3233 was also found to enhance the expression of genes associated with 
increased insulin signaling and sensitivity, such as peroxisome proliferator-activated   receptor 
gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4. In addition, glucose 
transporter 4 protein levels were seen to increase as a result of DLBS3233   administration. 
The combination of extracts also increased glucose uptake and adiponectin secretion, and 
decreased resistin secretion significantly relative to control cells. Moreover, DLBS3233 admin-
istered to insulin-resistant Wistar rats showed an ability to control blood sugar, insulin levels, 
and other lipoproteins, including high-density lipoprotein, low-density lipoprotein, triglycerides, 
and total cholesterol.
Conclusion: DLBS3233, as a combination of herbal extracts, holds promise in the treatment 
of type 2 diabetes, and possibly also in prevention of the disease.
Keywords: Lagerstroemia speciosa, Cinnamomum burmannii, peroxisome proliferator-
activated receptor gamma, glucose transporter 4
Introduction
In order to function, insulin binds to its receptor within the cell membrane. This 
mode of binding induces intracellular signaling pathway chain reactions, such as 
activation of glucose transporter enzymes and peroxisome proliferator-activated 
receptor gamma (PPARγ), peroxisome proliferator-activated receptor delta 
(PPARδ), and other transcription factors.1 Minor inhibition of signal transduction 
level will cause a decrease in insulin sensitivity. Among many classes of diabetes 
medication, the currently accepted medical treatment for increasing insulin sensi-
tivity is the thiazolidinediones (TZDs), including pioglitazone and rosiglitazone.1 
TZDs are substrates for the PPARγ transcription factor. Increasing the dosage of 
TZDs will increase gene expression of PPARγ, even though TZDs have been found 
to cause side effects, such as increased serum glutamic oxaloacetic transaminase 
and serum glutamic pyruvic transaminase levels (idiosyncratic acute hepatotoxic-
ity) and some edema.2International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Moreover, an insulin-resistant state is commonly 
associated with lipoprotein abnormalities that are risk fac-
tors for atherosclerosis, including hypertriglyceridemia, 
high levels of very low-density lipoprotein, low levels of 
high-density lipoprotein (HDL), and low levels of low-density 
lipoprotein (LDL). These metabolic abnormalities, together 
with hypertension and type 2 diabetes mellitus, may cluster in 
the same individual, causing the metabolic syndrome X.3
In this experiment, the biological activity of DLBS3233, 
a herbal extract combination containing Lagerstroemia 
speciosa and Cinnamomum burmannii, was investigated in 
a number of assays performed in 3T3-Swiss albino preadi-
pocytes and Wistar rats. In this assay, pioglitazone was used 
as a positive control for the TZD class and glimepiride was 
used as a positive control for sulfonylureas. Previous   studies 
showed that an extract from L. speciosa leaves could be 
used to decrease blood glucose levels in genetically diabetic 
rats and could also enhance glucose transport to adipocyte 
cells.4–6 According to Hattori et al,5 the biological activity 
of L. speciosa is attributable to several of its active com-
pounds (such as triterpene and corosolic acid) serving as 
insulin mimetics which can activate tyrosine kinase as an 
insulin receptor and inhibit tyrosine phosphatase. It is also 
believed that L.   speciosa works as a glucose transport acti-
vator and adipogenesis inhibitor in 3T3 Swiss albino cells.6 
In recent years, several studies have reported that cinnamon 
extract has an antidiabetic effect in db/db mice and in type 
2   diabetic patients.7 We investigated further the combination 
of L.   speciosa and C. burmannii to clarify the mechanism of 
action by which this combination decreases insulin resistance 
and increases glucose uptake.
Materials and methods
Materials
3T3 Swiss albino preadipocytes were obtained from the 
European Collection of Cell Culture (Salisbury, UK). 
Isobutyl-3-methylxanthine, dexamethasone, fetal calf serum, 
and trypsin-ethylenediamine tetra-acetic acid were purchased 
from Sigma Aldrich (St Louis, MO). Dulbecco’s Modified 
Eagle’s Medium (DMEM), L-glutamine, and penicillin/
streptomycin were obtained from Gibco BRL (Carlsbad, 
CA) while Trizol® was from Invitrogen (Carlsbad, CA). 
A One Step RNA PCR Kit RT, RNasin, dNTP mix, oligo dT, 
MgCl2, Taq polymerase, GoTaq Green master mix, Track It 
DNA Ladder 100 bp, and 3-(4,5-dimethylthiazol-2-yl)-2,5-
  diphenyltetrazolium bromide (MTT) were purchased from 
Promega (Madison, WI) while anthrone, fructose, and glucose 
was from Merck (Whitehouse Station, NJ). L. speciosa was 
obtained from Cianjur, West Java, Indonesia, while C. bur-
manii was purchased from Kerinci, Jambi, Indonesia. Both 
of these plants were identified by Herbarium   Bogoriense, 
Research Center for Biology, Indonesian   Institute of Sciences 
(Reference 1261/IPH.1.02/If.8/XII/2009).
Phytochemical characterization  
of DLBs3233
DLBS3233 was prepared as a polar extract in which 450 g 
of dried C. burmanii plant and 150 g of dried L. speciosa 
plant were mixed. The mixture was extracted simultaneously 
using a percolation technique in warm water (1:8–10) at a 
temperature of 50–90°C. The micelles were then filtered 
and dried using a Rotavapor (Büchi, Flawil, Switzerland) 
at a temperature of 40–50°C, and subsequently dissolved 
in methanol for further study. The yield of this experiment 
was about 6.5%.
DLBS3233 was identified using thin layer   chromatography. 
It was spotted on a 60 F254 silica gel plate and eluted using an 
eluent mixture of 1-butanol, acetic acid, water, chloroform, 
acetone, and formic acid (10:4:4:70:25:15). The eluent 
was allowed to move along the thin layer chromatography 
plate for a distance of 8 cm. Observation was done under 
ultraviolet light at 254 nm and 366 nm before and after a 
derivatization process using weak acid. In the chromatogram 
resulting from thin layer chromatography, it was observed 
that the components of DLBS3233 were extracted well. After 
the derivatization process was observed under ultraviolet 
light at 366 nm, a spot with Rf 0.6 showed that DLBS3233 
contained a concentrate of C. burmanii and an Rf 0.3 of 
L. speciosa.
The presence of polyphenol in DLBS3233 was   analyzed 
using a high-pressure liquid chromatography water 1525 binary 
high-pressure liquid chromatography pump with the Waters 
2487 dual λ absorbance as a detector. The   column used in this 
experiment was a Waters Atlantis dC18 (4.6 mm × 150 mm, 
5.0 µm). Its absorbance was measured at 279 nm. The gradi-
ent elutions used were acetic acid 0.05 N and acetonitrile at 
a flow rate of 1 mL/min, with the ratio changed at 30 and 
40 minutes. The polymer found in DLBS3233 is similar in 
chromatography to that found by Anderson et al,8 and hence 
it is suggested that the polymer is a polyphenol type A.
cell culture
3T3 fibroblast Swiss albino cells were maintained in high 
glucose DMEM containing 10% fetal calf serum, 2 mM 
L-glutamine, and 1% penicillin/streptomycin at 37°C in a 
humidified atmosphere of 5% CO2. Cells were subcultured International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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every 3–4 days at approximately 90% confluency. Three 
days before treatment, the cells were grown to about 
1 × 104 cells/mL on 10 cm diameter plates.
Adipocyte cell differentiation
3T3 fibroblast Swiss albino preadipocytes were grown 
(day 0) in a differentiation medium 1 (high-glucose DMEM, 
fetal calf serum 10%, dexamethasone 0.25 µM, isobutyl- 
3-methylxanthine 0.25 mM, and insulin 1 µg/mL), at about 
1 × 104 cells/mL in a 75 mL flask. Under these conditions, 
lipid accumulation was apparent in 5% of cells. On day 2, the 
medium was changed to a new differentiation medium 1. On 
day 3, the dexamethasone and isobutyl-3-methylxanthine were 
removed, leaving insulin on the cells. Cells were maintained 
in differentiation medium 2 (high-glucose DMEM, fetal 
calf serum 10%, and insulin 1 µg/mL), and the medium was 
changed every 2–3 days. Differentiation was observed by a 
visual method using microscopy. The 3T3 Swiss albino adi-
pocytes were found to be rounder in shape than the 3T3 Swiss 
albino preadipocytes. Under this supplemented condition, 
lipid droplets were observed in 15%–20% of the adipocytes, 
as assessed by oil red O staining (data not shown).
Immunoblotting with 
antiphosphotyrosine antibody
To analyze tyrosine phosphorylation at the insulin   receptor, 
cells prepared in sample buffer were centrifuged at 5000 rpm 
for 10 minutes. The supernatants were subjected to electro-
phoresis on 8% sodium dodecyl sulfate gel.   Proteins were 
electrophoretically transferred to a supported nitrocellulose 
membrane. The membrane was blocked with nonspecific 
proteins (Block I, 5% wt/vol powdered skimmed milk in 
phosphate-buffered saline). After primary blocking, the 
membrane was incubated overnight with fresh Block I 
and polyclonal anti-IRS-1 antibody. The next day, after the 
appropriate washes (phosphate-buffered saline followed by 
Tris/NaCI [50 mmol/L Tris, 150 mmol/L NaCI, pH 7.5]), the 
nitrocellulose membrane was incubated with the secondary 
antibody, ie, rabbit-antimouse horseradish peroxidase con-
jugate (Sigma). The blotted nitrocellulose membrane was 
treated with enhanced chemiluminescence substrates (ECL, 
Amersham, Arlington Heights, IL) and the membrane was 
used to expose X-ray films.
Insulin-resistant preadipocytes
In order to make an insulin-resistant cell, either preadipo-
cytes or adipocytes were maintained for more than 2 weeks 
in very high-glucose DMEM containing 10 mg/mL glucose, 
10% fetal calf serum, 2 mM L-glutamine, and 1% penicillin/
streptomycin at 37°C in a humidified atmosphere of 5% CO2. 
Cells were subcultured every 3–4 days to reach approximately 
90% confluency.
extract administration
Before administration of the extract, the cell medium 
was changed to a serum-free medium. Both the extract 
(1–5 µg/mL) and positive controls (pioglitazone and 
glimepiride) were administered and incubated for 48 hours. 
Extracts of C. burmanii and L. speciosa was also adminis-
tered separately to the cells in order to observe the effect of 
each plant alone compared with their combination.
rnA isolation
Total RNA was extracted using Trizol from 3T3 cells fol-
lowing the manufacturer’s instructions. In brief, the cells 
were lysed in Trizol reagent and extracted using chloroform, 
followed by isopropanol precipitation at 4°C for about 
1–4 hours. The pellet was suspended by double-distilled 
H2O or nuclease-free water and stored at −20°C prior to use. 
Concentration and purity level (A260:A280) was determined 
by optical density measurement using a spectrophotometer 
(BioRad, Hercules, CA) at a 260 nm wavelength, and then the 
integrity of the RNA was verified using gel electrophoresis 
to detect the 28S and 18S ribosomal band.
reverse transcription polymerase  
chain reaction
Prior to the reverse transcription process, RNA was incubated 
at 65°C for 10 minutes. The reverse transcription reaction 
was conducted in 25 µL of 1 µg RNA, 5 µL of 5 × buffer 
AMV reverse transcriptase, 0.5 µL of RNasin 40 U/µL, 
2.5 µL of dNTP mix 10 mM, 1 µL of Oligo dT 500 µg/mL, 
0.5 µL of AMV reverse transcriptase 10 U/µL, and double-
distilled H2O until a total volume of 25 µL was obtained. 
Conditions for the reverse transcription step of RNA included 
  hybridization at 30°C for 10 minutes, reverse transcription 
at 45°C for 45 minutes, denaturation at 99°C for 5 minutes, 
and continued at 6°C for 5 minutes. The reverse transcription 
product, ie, cDNA, was stored at −20°C prior to use.
Gene expression analysis
Analysis of gene expression was measured at the mRNA 
level. Polymerase chain reaction was performed to amplify 
the specific gene using specific oligonucleotide primers 
designed by Primer 3 software. The gene sequences were 
obtained from the GenBank database. Genes involved in International Journal of General Medicine 2011:4
Table 1 Primers used to amplify region of interest in Pcr
Gene name Primer sequences PCR product (bp)
PI3 kinase sense: 5′-GAA GAc TGA GAG Gcc AcG Ac-3′
Antisense: 5′-cTT GTA ATc cAT GGc GTc cT-3′
180
Akt sense: 5′-AcT GTT cAG AGA GGc cAG GA-3′
Antisense: 5′-cGG TTG ccT AcT GGT TcA AT-3′
181
PPARγ sense: 5′-GcT GTG cAG GAG ATc AcA GA-3′
Antisense: 5′-ccc cTc cAT AAA cTc Acc AA-3′
229
GLUT4 sense: 5′-AcT cTT Gcc AcA cAG GcT cT-3′
Antisense: 5′-AAT GGA GAc TGA TGc GcT cT-3′
174
Adiponectin sense: 5′-GTT GcA AGc TcT ccT GTT cc-3′
Antisense: 5′-TcT ccA GGA GTG ccA TcT cT-3′
192
Resistin sense: 5′ GcT GAG GGT cTG GAA ATG AA-3′
Antisense: 5′ GGc cAG ccT GGA cTA TAT GA-3′
223
Beta actin (internal control) sense: 5′ AGA GGG AAA TcG TGc GTG Ac 3′
Antisense 5′ cAA TAG TGA TGA ccT GGc cGT 3′
138
Abbreviations: Pcr, polymerase chain reaction; PPARγ, peroxisome proliferator-activated receptor gamma; PI3, phosphatidylinositol-3.
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insulin signal transduction (phosphatidylinositol-3 [PI3] 
kinase, Akt, PPARγ, glutamine transporter 4 (GLUT4), 
adiponectin, and resistin, the specific primers for which are 
shown in Table 1) were detected using a reverse transcrip-
tion polymerase chain reaction. The amplification reaction 
for the genes was carried out in a 25 µL mixture of solution 
containing 12.5 µL of Go Taq Green master mix, a pair of 
target genes with a final concentration of 0.9–1.2 µM, a 
pair of internal controls (beta actin) with a final concentra-
tion of 0.08–1.0 µM, 5 µL of cDNA, and double-distilled 
H2O. Polymerase chain reaction conditions for each target 
gene were similar to each other, and generally consisted 
of initial denaturation at 95°C for 3 minutes, 30–40 cycles 
of denaturation at 95°C for 30 seconds, primer annealing   
at 56–60°C for 30 seconds, and elongation at 72°C for 
1 minute. When necessary, an additional elongation reaction 
was performed at 72°C for 10 minutes. Reverse transcrip-
tion polymerase chain reactions were done using the PCR 
iCycler (BioRad). Target gene expression was expressed 
quantitatively, reflecting a ratio of the target gene product 
bands to an internal control band, and calculated according 
to the formula supplied in the manufacturer’s manual and 
using Image J Imaging System software (v 1.24; National 
Institutes of Health, Bethesda, MD).
Quantifications of GLUT4 protein
Total protein of 3T3 cells was extracted and separated by 
SDS-PAGE 10%. They were then transferred onto PVDF 
membranes (Millipore, Bedford, MA). HRP-conjugated 
secondary antibodies and chemiluminescence system were 
applied for the detection of blots. Images were acquired 
using an LSD-4000 chemiluminescence Imager (Fujifilm, 
Tokyo, Japan). Band intensities were quantified using Image 
J software (National Institutes of Health).
In vitro glucose uptake activity assay
Glucose uptake activity was analyzed by measuring the 
ratio of exogenously administered glucose concentrations 
with those found after a period of incubation. Measurement 
of glucose concentration was performed via the reaction of 
glucose with anthrone in strong sulfuric acid.9 Cells were 
grown to about 1 × 104 cells/mL in 6 cm diameter plates. 
  3T3-Swiss albino cells were maintained in high-glucose 
DMEM containing 10% fetal calf serum, 2 mM L-glutamine, 
and 1% penicillin/streptomycin at 37°C in a humidified 
atmosphere of 5% CO2. Briefly, confluent cells were washed 
twice with phosphate-buffered saline and incubated with 
3 mL glucose solution 10 mg/mL with or without administra-
tion of DLBS3233 extract at 37°C for 0, 2, 4, and 6 hours. 
During incubation the cells took up glucose, enabling free 
glucose to be measured in the media, from which the con-
centration of glucose uptake could then be determined. The 
concentration of glucose taken up by the cells is described 
by the equation:
[glucose uptake] =   [initial glucose] 
− [free glucose within media],  and
%glucoseuptake
freeglucose
withinmedia
initial
glucose
=
− 
 

 


 

  []
×
initialglucose
100%
Anthrone was dissolved in H2SO4 prepared by adding 
concentrated acid to water. This anthrone solution is ready 
to be used after incubation for at least 2 hours and must be International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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used within 24 hours. The reaction of anthrone and glucose 
was analyzed by the following procedure. Portions of the 
free glucose solutions in each well plate were transferred 
into test tubes. Each tube was placed in a water bath while 
anthrone reagent was added. The tubes were transferred to 
a boiling water bath for several minutes, and then stored in 
a dark room for a few minutes. The optical densities of the 
colored solutions were measured using a spectrophotometer 
(BioRad) at 625 nm. The increase in glucose uptake after 
administration of DLBS3233 was calculated according to the 
formula supplied in the manufacturer’s manual using Image 
J Imaging System software.
Animal experiment
Wistar rats (male, eight weeks old, 200–220 g) were obtained 
from D’Wistar (Bandung, Indonesia). The animal study was 
conducted with approval from the ethical institutional advisory 
committee as suggested by the Association for Assessment 
and Accreditation of Laboratory Animal Care (AAALAC). 
Animals were individually housed according to the guidelines 
of AAALAC and maintained at 25°C with a 12-hour light/dark 
cycle. The animals were given free access to water. They had 
been acclimatized for 1 week before treatment. The rats were 
separated into three groups. The first group (n = 7) comprised 
controls maintained on a standard diet. The second (n = 7) and 
third (n = 7) groups were maintained on a high-glucose diet 
for two weeks, with fructose 15% and glucose 10% to make 
them insulin-resistant. The third group was later treated with 
DLBS3233 at 9 mg/kg body weight for another 2 weeks. After 
the end of the treatment period, blood samples were collected 
from the tail vein of each rat to measure the random glucose 
level. Later, the rats in each group were fasted overnight, 
fed, and 2 hours later, blood samples were taken to measure 
postprandial glucose. Animals were fasted overnight again, 
blood samples were collected by cardiac puncture, and cen-
trifuged at 8500 g for 25 minutes. The serum was separated 
out to measure the level of fasting glucose, insulin, triglyc-
erides, total cholesterol, LDL, and HDL. An ultrasensitive 
rat insulin enzyme-linked immunosorbent assay (Mercodia, 
Uppsala, Sweden) and microplate reader (BioRad) were used 
to measure the insulin level. Other tests were carried out using 
a semiautomated clinical chemistry analyzer (Vital Scientific, 
the Netherlands). In addition, homeostasis model assessment 
was calculated by multiplying the glucose (mmol/L) by the 
insulin concentration, then dividing by a factor of 22.5.10 The 
data were analyzed using one-way analysis of variance, and the 
significance level was measured by the post hoc Bonferroni 
test using Biostat software (Alexandria, VA).
statistical analyses
Statistical differences in test and control samples were 
determined by Student’s t-test or ANOVA using Statview 
software (Abacus Concepts, Inc, Berkeley, CA). Data shown 
are from a representative experiment which was performed 
in duplicate or triplicate.
Results
Glucose uptake in normal and insulin-
resistant preadipocytes/adipocytes
In order to study glucose uptake in different adipocyte 
conditions, the 3T3 fibroblast Swiss albino cells were 
allowed to differentiate into mature adipocytes so that 
they could be used as a cellular model of insulin resis-
tance in diabetes. In the insulin-resistant condition, their 
glucose uptake capacity was used to simulate the actual 
phenomenon in the clinical setting. It was found that the 
insulin-resistant preadipocytes and mature adipocytes 
took up glucose at a much lower rate than their normal 
counterparts (Figure 1A). In addition, the onset of glucose 
uptake was found to be earlier in normal preadipocytes and 
adipocytes when compared with those that were insulin-
resistant. This suggests that glucose transport impairment 
had occurred in the insulin-resistant preadipocytes and 
adipocytes, a clinically important phenomenon in predict-
ing the onset of type 2 diabetes even in seemingly normal 
individuals.
effect of DLBs3233 versus pioglitazone 
on glucose uptake
In order to investigate the glucose transport profile in adipo-
cytes, glucose uptake assays were performed in normal and 
insulin-resistant adipocytes at different times (1 and 6 hours) 
following exogenous glucose administration. In general, the 
uptake took place as early as 1 hour in most cells (A–J), and 
the longer the duration of exposure, the higher the uptake 
(1–6 hours, Figure 1B). In addition, it was seen that the resistant 
cells took up less glucose than did the normal cells, a phenom-
enon seen previously in Figure 1. Pioglitazone 0.02 µm was 
used as a positive control. Addition of pioglitazone to insulin-
resistant adipocytes led to a 1.5-fold increase in glucose uptake 
compared with non-pioglitazone-treated adipocytes (I versus 
H). Similarly, addition of DLBS3233 to normal or insulin-
resistant cells led to a 1.5–2.0-fold increase in glucose uptake 
compared with control cells (D versus B in normal cells; J 
versus H in their resistant counterparts). These data suggest 
that an insulin sensitizer works well for increasing glucose 
uptake into cells and thus lowers blood glucose levels.International Journal of General Medicine 2011:4
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Figure 1 DLBs3233 increases glucose uptake in 3T3 swiss albino cells compared with untreated cells. A) Glucose uptake level of 3T3 swiss albino preadipocytes and 
adipocytes in normal and insulin-resistant condition. B) effect of DLBs3233 5 µg/mL and pioglitazone 0.02 µM on glucose uptake in normal and insulin-resistant 3T3 swiss albino 
adipocytes. C) DLBs3233 5 µg/mL enhances glucose uptake activity of 3T3 swiss albino insulin-resistant adipocytes as potently as pioglitazone in time-dependent manner.
results are mean value ± standard deviation of two independent experiments.
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effect of DLBs3233 on glucose uptake  
in insulin-resistant adipocytes
The capacity for glucose uptake before treatment in 3T3 insu-
lin-resistant Swiss albino adipocytes was found to be less than 
5% (control cells). However, after DLBS3233 treatment, the 
uptake capacity was increased by about 20%, as shown in 
Figure 1C. Similar results were found when the cells were 
treated with pioglitazone. This suggests that DLBS3233 is as 
potent as pioglitazone in inducing glucose uptake.
Induction of PPARγ gene expression  
in 3T3 preadipocytes
In order to confirm the activity of DLBS3233 as a combina-
tion compared with each plant it is derived from, the effects 
of C. burmanii and L. speciosa on PPARγ gene expression 
were studied individually. It can be seen in Figures 2A and 2B 
that neither C. burmanii nor L. speciosa had any significant 
effect on PPARγ  gene expression when used alone. The level 
of gene expression appeared to be similar after administra-International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Figure 2 Peroxisome proliferator-activated receptor gamma gene expression after administration of Cinnamomum burmanii extract (A), Lagestroemia speciosa extract (B), and 
DLBs3233 (C) at various concentrations.International Journal of General Medicine 2011:4
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Figure  3  effect  of  DLBs3233  5  µg/mL  on  expression  of  tyrosine  phosphorylation  (A).  The  effect  of  DLBs3233  5  µg/mL  and  pioglitazone  0.02  µM  in  enhancing 
phosphatidylinositol-3 kinase (B) and Akt (C) gene expression in 3T3 swiss albino preadipocytes. The effect of DLBs3233 1–5 µg/mL in enhancing glucose transporter 4 gene 
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tion of both these plants compared with controls. These data 
suggest that, when used in combination, C. burmanii and L. 
speciosa interact with each other, causing the native charac-
teristics of each extract to work synergistically to strengthen 
their pharmacological activity.
Moreover, the effect of DLBS3233 on PPARγ  expression 
at the mRNA level was compared with that of pioglitazone and 
glimepiride. The DLBS3233 concentration which stimulated 
the highest PPARγ  mRNA expression was 5 µg/mL (Fig-
ure 2C). This concentration of DLBS3233 enhanced PPARγ 
expression to a 1.8-fold greater extent than in the control cells. 
On the other hand, administration of pioglitazone 0.02 µM to 
3T3 Swiss albino cells enhanced PPARγ expression by only 
1.5-fold compared with the control cells, whereas glimepiride 
0.02 µM did not result in any effect. This result suggests that 
DLBS3233 may contain bioactive compound(s) that can act as 
a direct ligand for PPARγ. In other words, DLBS3233 may reg-
ulate the expression of PPARγ  either directly or indirectly.
effect of DLBs3233 on tyrosine 
phosphorylation
In this experiment, administration of DLBS3233 pro-
moted tyrosine phosphorylation at the insulin   receptor in 
a   dose-dependent manner (Figure 3A). The   concentration 
of DLBS3233 used in this experiment was in the range 
of 20–100 µg/mL. The administration of exogenous 
insulin (10 nM and 100 nM) also promotes tyrosine 
phosphorylation.
Induction of PI3 kinase gene expression in 
3T3 preadipocytes
This study measured the activation of PI3 kinase as a broad 
indicator of insulin action in the overall insulin signal trans-
duction pathway. The effect of DLBS3233 on induction of 
PI3 kinase expression at the mRNA level was compared 
with that of pioglitazone. The DLBS3233 concentration 
which stimulated the highest PI3 kinase mRNA expression International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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was 5 µg/mL (Figure 3B). This concentration of DLBS3233 
enhanced PI3 kinase expression to a 1.7-fold greater extent 
than in the control cells. Such enhancement was found to be 
even higher than that demonstrated by 0.02 µM pioglitazone 
(1.25 times greater than in controls). This result suggests 
that DLBS3233 action may involve compound(s) which 
can directly or indirectly activate(s) the insulin receptor, 
tyrosine kinase.11
Induction of Akt gene expression 
in 3T3 preadipocytes
The effect of DLBS3233 on the induction of Akt expression 
at the mRNA level was compared with that of pioglitazone. 
The concentration of DLBS3233 that stimulated the greatest 
Akt expression in 3T3 cells was 5 µg/mL (Figure 3C). This 
concentration enhanced Akt expression to a 1.5-fold greater 
extent than that seen in the control cells. This value was 
slightly greater than that for pioglitazone 0.02 µM, which 
enhanced Akt expression to a 1.4-fold greater degree than 
in control cells. This result indicates that expression of the 
Akt effector of PI3 kinase is activated by DLBS3233 and 
pioglitazone, and this is an important event in the process 
of conferring insulin sensitivity.12
Induction of GLUT4 gene expression  
by DLBs3233
To study the activity of DLBS3233 as a glucose transport stimu-
lant, an analysis of GLUT4 gene expression was undertaken. The 
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concentration of DLBS3233 that stimulated the highest GLUT4 
expression in 3T3 cells was 5 µg/mL   (Figure 3D), and could 
enhance GLUT4 expression to a 1.9-fold greater extent than in 
control cells (Figure 3E). This result indicates that DLBS3233 
extract significantly increased GLUT4 expression, leading to 
increased glucose uptake in cells, as shown in Figure 1.
In addition, the upregulation of GLUT4 expression by 
DLBS3233 was compared with that of pioglitazone in the 
presence and absence of insulin (Figure 3E). It was found 
that DLBS3233 at the concentration of 5 µg/mL induced the 
expression of GLUT4 by up to 2-fold compared with controls, 
exceeding that of pioglitazone (1.25-fold) and that of insulin 
alone (1.35-fold).
effect of DLBs3233 on GLUT4  
protein levels
We examined GLUT4 protein levels and showed that 
DLBS3233 5 µg/mL increased total GLUT4 in adipocytes to 
an approximately 2.5-fold greater extent than in control cells 
(P , 0.05, Figure 3F). These data are in accordance with the 
level of GLUT4 expression at the RNA level after DLBS3233 
administration, which indicates that DLBS3233 could control 
GLUT4 at both the RNA level and protein level.
effect of DLBs3233 on adiponectin  
and resistin expression in 3T3-swiss  
albino cells
The effect of DLBS3233 on adiponectin and resistin expres-
sion was explored. The administration of DLBS3233 showed 
an increase of adiponectin expression to a 1.7-fold greater 
extent than in controls, while the administration of pioglita-
zone did not show a significant effect (Figure 4A).
We also investigated the expression of resistin as a marker 
of insulin resistance in response to DLBS3233 with or without 
insulin. A decrease in resistin gene expression was observed in 
the DLBS3233-treated group (Figure 4B). These data suggest 
that insulin resistance in 3T3 cells decreased as expected. In 
this regard, administration of DLBS3233 5 µg/mL decreased 
80% of resistin expression compared with the control group, 
even in the presence of insulin. Moreover, the combination of 
insulin and DLBS3233 reduced gene expression by more than 
that achieved by a combination of insulin and pioglitazone.
effect of DLBs3233 on glucose,  
triglycerides, total cholesterol, LDL,  
and hDL levels
The effect of DLBS3233 on blood glucose control was also 
observed in vivo using animal models. The administration 
of a high-glucose diet increased the concentration of blood 
glucose by up to 41.33% in normal conditions, by 49.02% in 
2-hour postprandial conditions, and by 60.22% in overnight 
fasting conditions. It also increased insulin, total cholesterol, 
LDL, and triglyceride levels by up to 220.38%, 59.59%, 
31.70%, and 61.39%, respectively. On the other hand, HDL 
levels decreased by up to 17.15%.
Treatment with DLBS3233 9 mg/kg body weight for a 
further 2 weeks achieved a significant decrease in random 
glucose (by 29.64%, Figure 5A), postprandial glucose 
(by 30.62%, Figure 5B), and fasting glucose (by 31.41, 
  Figure 5B). Similar results were also found for other bio-
chemical parameters, including for insulin (Figure 5D), 
triglycerides (Figure 5E), total cholesterol (Figure 5F), 
and LDL levels (Figure 5G), with decreases of 64.71%, 
33.78%, 21.36%, and 30.81%, respectively. The levels 
of these biochemical parameters were lower when com-
pared with those in the insulin-resistant group, and were 
approximately equal to those reached in normal conditions. 
Moreover, HDL levels in insulin-resistant rats treated with 
DLBS3233 were almost the same as normal, and 18.20% 
higher compared with levels in the insulin-resistant group 
(Figure 5H).
Furthermore, fasting glucose and insulin levels for each 
individual rat were compared, and are shown in Figure 5I. 
Insulin and fasting glucose levels were both increased in 
Group 2, and as the graph indicates, were far from those 
seen in the normal condition. However, after DLBS3233 was 
administered, the fasting glucose and insulin levels became 
similar to those in the normal condition. This comparison 
was used further to evaluate fasting glucose and insulin 
levels in each group, and were expressed by homeostasis 
model assessment. The calculation result shows that the 
homeostasis model assessment in the insulin-resistant group 
was increased up to five-fold, and then decreased significantly 
after treatment with DLBS3233 (Figure 5J).
Discussion and conclusion
In this gene expression study, we have demonstrated 
that DLBS3233, a standardized herbal extract containing 
L.   speciosa and C. burmannii, acts as an insulin sensitizer via 
modulation of PPARγ. Initially, we found that the capacity 
and time course of DLBS3233 glucose uptake was compa-
rable with that of pioglitazone (Figure 1). However, addition 
of insulin to DLBS3233 did not increase glucose uptake 
at the 6-hour treatment, although it shortened the time for 
onset of action to 2 hours as opposed to 4 hours, achieving 
its maximum uptake in the fourth hour. This suggests that an 
additional insulin pool is needed for DLBS3233 to work as an 
insulin sensitizer and activator of glucose uptake. A similar International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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finding has been found for rosiglitazone, which belongs to 
the TZD class.1
TZDs comprise a new class of orally active drugs that 
are designed to enhance the actions of insulin. These agents 
reduce insulin resistance by increasing insulin-dependent glu-
cose disposal and reducing hepatic glucose output. Although 
the precise mechanism of action of these drugs remains 
unknown, transcriptional changes are observed in tissue 
culture cells that enhance insulin action. This regulation of 
gene expression appears to be mediated by the interactions 
of the TZDs with the PPAR family.13
Our results show that DLBS3233 has the capacity to 
increase PPARγ expression (Figure 2C) similar to the TZD 
class of drugs. The PPARs compose a nuclear receptor sub-
family and consists of three isoforms, α, δ, and γ, which are 
encoded by three separate genes.14 These are ligand-regulated 
transcription factors, the main physiological actions of which 
are mediated by altering gene expression. PPARγ is highly 
expressed in adipose tissue. Activation of PPARγ  induces 
adipocyte differentiation and lipid accumulation in adipo-
cytes by modulating numerous genes regulating adipogenesis, 
lipid uptake, and lipid metabolism. Hence, it can be inferred 
that DLBS3233 has the same mechanism of action as that 
of the TZD class in increasing cellular glucose uptake15 and 
insulin sensitivity.
Based on these data, we performed a DLBS3233 study 
of PI3 kinase because PPARγ plays an important role in 
regulating this enzyme, which has a pivotal role in mediating 
the biological actions of insulin through IRS-1 and 2.11,16 It 
was found that DLBS3233 enhanced PI3 kinase expression 
to an even greater extent than pioglitazone (Figure 3B). 
This fi  nding was confirmed by the increase in tyrosine 
  phosphorylation upstream of PI3 kinase, as well as in Akt, a 
downstream effector of PI3 kinase.
Tyrosine phosphorylation is the beginning of the intra-
cellular signal transduction pathway which activates PI-3 
kinase.17,18 The presence of glucose and insulin will stimulate 
this phosphorylation. As expected, administration of insulin 
promotes tyrosine phosphorylation. This experiment also 
showed that DLBS3233 promotes this phosphorylation 
(  Figure 3A), which is consistent with the previous result 
showing that DLBS3233 works via the insulin signaling 
pathway.
Akt, also known as protein kinase B, is a member of 
the serine/threonine-specific protein kinase family.11,12 It is 
an important signaling molecule in the insulin signaling 
pathway. It is required for the insulin-induced translocation 
of GLUT4 to the plasma membrane.12,13 It has been found 
previously that impaired insulin-stimulated glucose transport 
is responsible for reducing the rate of insulin-stimulated 
muscle glycogen synthesis in patients with type 2 diabetes 
mellitus.19 A pathway in which GLUT4 is expressed on the 
plasma membrane begins with insulin binding to the receptor 
in its dimeric form.11,16,19 The receptor phosphorylates and 
subsequently activates IRS1, which converts PIP2 to PIP3. 
PIP3 is bound to Akt, signaling for PDK1 to phosphorylate 
Akt.11 Once phosphorylated, Akt is in its active form and 
phosphorylates other targets that stimulate GLUT4 to be 
expressed on the plasma membrane.12 This result indicates 
that DLBS3233 is a stimulator of glucose transport because 
it upregulates GLUT4 expression (Figure 3E). This result 
corresponds with the increase in total GLUT4 protein levels 
(Figure 3F).
In addition to its effect on the PI3/Akt pathway, 
DLBS3233 was shown to upregulate adiponectin   (Figure 4A) 
and downregulate resistin (Figure 4B). Adiponectin, which is 
regulated by PPARγ, is a 30 kDa protein containing a short 
central collagenous region and a C-terminal tumor necrosis 
factor alpha-like domain.20 It potentiates inhibition of hepatic 
gluconeogenesis by insulin, and therefore its levels are 
reduced in obese insulin-resistant subjects and type 2 dia-
betics.21 Additionally, resistin, which is another gene known 
to be associated with type 2 diabetes, was also observed in 
this study. It has recently been identified as a novel derived 
hormone.22 Results of the adiponectin and resistin study 
are in agreement with our previous observation indicating 
that the mechanism of action for DLBS3233 is via PPARγ, 
thereby increasing insulin sensitivity and reducing insulin 
resistance.
The effect of DLBS3233 was further seen in the Wistar 
rat study. The rats were rendered insulin-resistant by admin-
istration of fructose and glucose, leading to uncontrolled 
insulin action. Fructose stimulates hepatic production of 
triglycerides by promoting the re-esterification of circulating 
nonesterified fatty acids and by stimulating de novo fatty acid 
synthesis. Increased delivery of triglycerides or nonesteri-
fied fatty acids to the muscle interferes with the utilization 
of glucose, impairing insulin action.3 Administration of 
DLBS3233 to insulin-resistant rats brought the levels of 
glucose, insulin, lipoproteins, total cholesterol, and triglyc-
erides into the normal range (Figures 5A–5H). Moreover, the 
homeostasis model assessment index was reduced to normal 
after DLBS3233 administration, suggesting that DLBS3233 
was able to control the insulin resistance (Figures 5I–5J). 
The homeostasis model assessment is often used to assess 
insulin resistance and beta cell function, and requires only International Journal of General Medicine
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fasting glucose and insulin levels.23 It had high sensitivity 
and specificity for measuring insulin resistance.24
Taken together, these data suggest that DLBS3233 has the 
activity to control blood sugar, insulin, and other lipoproteins, 
including HDL, LDL, triglycerides, and total cholesterol. 
Currently, clinical trials of DLBS3233 are underway in a 
number of hospitals. The value of such an herbal drug in 
the treatment of diabetes in terms of insulin resistance will 
be meaningful in light of the recent finding that TZDs can 
actually increase cardiovascular risk in already burdened 
patients.
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